Data updated: May 26, 2026
FUROSCIX (furosemide)
Trial Activity: Declining 8 active trials
Cardiovascular
Approved 2022-10-07
FUROSCIX is indicated for the treatment of Edema; Chronic Heart Failure; Chronic Kidney Disease; Nephrotic Syndrome.
Source: FDA Label • SCPHARMACEUTICALS
Development Insights
Boehringer Ingelheim conducting 6 trials (8%)
75 indications explored (Broad Platform)
→ healthy (9 trials)
→ heart failure (9 trials)
→ acute heart failure (4 trials)
4
Indications
--
Phase 3 Trials
3
Years on Market
Details
- Status
- Prescription
- First Approved
- 2022-10-07
- Patent Cliff
- 2034
- Routes
- SUBCUTANEOUS
- Dosage Forms
- SOLUTION
FUROSCIX Approval History
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
4 FDA actions from 2022 to 2025 · 3 indication expansions
What FUROSCIX Treats
4 indicationsFUROSCIX is approved for 4 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Edema
- Chronic Heart Failure
- Chronic Kidney Disease
- Nephrotic Syndrome
Source: FDA Label
FUROSCIX Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
10
Same indication, different mechanism — what else might this patient receive?
Unlock 8 more competitors across all three rings.
Upgrade to Pro Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to FUROSCIX
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
📋
Clinical Trial Registry
71 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05915286 DIURESED | Pro00119451 | Ph 4 | terminated | Diuretic Use in Hemodialysis Patients With Residual Renal Function |
| NCT06941415 BUFF | IRB_00186841 | Ph 3 | not yet recruiting | Bumetanide vs. Furosemide in Cirrhosis |
| NCT05470283 | 2022-0356 NCI-2022-06873 | Ph 1 | active not recruiting | Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma |
| NCT06899061 | D9723C00002 2024-513692-41-00 | Ph 1 | active not recruiting | Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib |
| NCT07431866 | 2828-005 | Ph 1 | recruiting | A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) |
| NCT03892148 ProDUCT-HF | CHU-428 2018-A02971-54 | Ph 4 | completed | Protocol of Diuretics Use in Congestive Therapy in Heart Failure |
| NCT06036914 results posted | 23-005262 | Ph 2 | completed | A Study of Ultra High Dose Diuretics to Treat Heart Failure |
| NCT06504862 results posted | 1479-0015 2024-510628-38-00, U1111-1302-1171 | Ph 1 | completed | A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood |
| NCT04481789 results posted | MT-1186-J02 | Ph 1 | completed | Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study) |
| NCT05779943 results posted | STUDY00004720 RAD5689-22-BED-IIT-439, STUDY00004720 | Ph 2 | active not recruiting | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer |
| NCT03296813 TRANSFORM-HF results posted | Pro00080595 U01HL125511-01A1 | Ph 3 | completed | TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure |
| NCT07173738 | BIA-51058-111 2017-002807-93 | Ph 1 | completed | Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide |
| NCT05986773 P-Value-AHF | P-Value-AHF | Ph 4 | terminated | Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance |
| NCT04180397 GODIF | GODIF | Ph 4 | recruiting | Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit. |
| NCT05079789 AMILOR results posted | AmiloridNS-01 2019-002607-18 | Ph 3 | terminated | Amiloride in Nephrotic Syndrome |
| NCT04752475 LAPP results posted | AAAT2525 | Ph 3 | completed | Lasix for the Prevention of De Novo Postpartum Hypertension |
| NCT05981365 results posted | GBT440-0122 C5341029 | Ph 1 | completed | Voxelotor CYP and Transporter Cocktail Interaction Study |
| NCT05093621 TFO results posted | 2000029589 | Ph 3 | completed | Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure |
| NCT02163655 DIUPRE | DIUPRE DIUPRE | Ph 4 | completed | Diuretics for Postpartum High Blood Pressure in Preeclampsia |
| NCT04615624 results posted | 2020-003 | Ph 3 | completed | Furosemide vs. Placebo for Severe Antepartum Hypertension |
| NCT06218199 DART-HA | Dart-HA | Ph 4 | recruiting | Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts |
| NCT02574845 results posted | 352.2094 2015-003052-46 | Ph 1 | completed | DDI (Effect of Metformin and Furosemide on Rosuvastatin PK) |
| NCT02854527 results posted | 352.2096 2016-001893-14 | Ph 1 | completed | Transporter Cocktail Mutual Interaction |
| NCT03307252 results posted | 0352-2100 2017-001549-29 | Ph 1 | completed | This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men |
| NCT02231931 | 352.2082 2014-001940-40 | Ph 1 | completed | Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin |
| NCT04343235 results posted | 06784 | Ph 4 | terminated | Postpartum Management of Gestational Hypertensive Disorders Using Furosemide |
| NCT05620784 | STU00217795 | Ph 3 | recruiting | Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP |
| NCT03362515 results posted | 17D.264 | Ph 2 | terminated | Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide |
| NCT05768360 | D5084C00014 2022-003785-21 | Ph 1 | completed | A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects |
| NCT05158153 ORKID results posted | 21-33602 | Ph 4 | terminated | Outpatient Recovery From Acute Kidney Injury Requiring Dialysis |
| NCT02450773 | 201501157 | Ph 2 | withdrawn | Prevention of Severe Postpartum Hypertension |
| NCT05840536 COMBIND-HF | OchsnerHS | Ph 4 | withdrawn | Combination Diuretic Therapy for Acute Decompensated Heart Failure |
| NCT01156220 | IPT0901 | Ph 4 | withdrawn | Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers |
| NCT04763226 | CV021-004 | Ph 1 | completed | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants |
| NCT03901729 AVANTI | 17909 2018-004059-18 | Ph 2 | completed | A Trial to Study BAY1753011 in Patients With Congestive Heart Failure |
| NCT02345681 IRIHS-REA | RC14_0268 | Ph 3 | completed | Impact of Rational Control of Fluid Balance in the Intensive Care Unit |
| NCT03730961 results posted | CV013-034 2018-000970-31 | Ph 2 | completed | An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic |
| NCT04691687 OUTLAST | 307139 307139 | Ph 4 | completed | OUTpatient Intravenous LASix Trial in Reducing Hospitalization for Acute Decompensated Heart Failure |
| NCT03731117 FURTHER | P170404J | Ph 4 | terminated | FURosemide Stress Test to Predict Need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in ICU |
| NCT04628325 | UPalermo | Ph 3 | completed | Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) |
| NCT02531581 | 14-AOI-11 | Ph 4 | completed | Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive |
| NCT02183792 AQUA-AHF results posted | HS-13-00705 | Ph 4 | completed | Aquaresis Utility for Hyponatremic Acute Heart Failure Study |
| NCT02960412 | Pro00026976 | Ph 4 | completed | Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy |
| NCT03801759 | AKB-6548-CI-0031 | Ph 1 | completed | Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide |
| NCT02877095 SUBQ-Pilot results posted | Pro00070399 | Ph 1 | completed | Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot |
| NCT02767024 PRIORITY-ADHF | 2014-3586 | Ph 4 | withdrawn | Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure |
| NCT01558674 results posted | 7145-011 | Ph 1 | terminated | A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011) |
| NCT01901809 ROPA-DOP results posted | NA 00083629 | Ph 4 | completed | Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction |
| NCT02351934 results posted | 14-008292 UL1TR000135 | Ph 4 | completed | Early Diuresis Following Colorectal Surgery |
| NCT02524054 results posted | 2011P000027 R01NR012009 | Ph 1, Ph 2 | completed | Aerosol Inhalation Treatment for Dyspnea - Patients |
Showing 50 of 71 trials
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
FUROSCIX FDA Label Details
Indications & Usage
FDA Label (PDF)FUROSCIX is indicated for the treatment of Edema; Chronic Heart Failure; Chronic Kidney Disease; Nephrotic Syndrome.
View full patent landscape →
4 OB patents · 1 families ·
41 international docs across 16 countries
FUROSCIX Patents & Exclusivity
Latest Patent: Apr 2034
Patents (4 active)
US11433044
Expires Apr 3, 2034
US9884039
Expires Apr 3, 2034
US12370168
Expires Apr 3, 2034
US10272064
Expires Apr 3, 2034
Source: FDA Orange Book
Pro Intelligence Preview
Deep insights for FUROSCIX
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2034
- • 4 active patents
Trial Analysis
- • 75 total trials
- • Stage: Declining
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Unlock Full Intelligence
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment